We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+45.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$396M
AUM Growth
+$81.5M
Cap. Flow
-$53.8M
Cap. Flow %
-13.59%
Top 10 Hldgs %
82.26%
Holding
45
New
14
Increased
6
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
CASC
Cascadian Therapeutics, Inc.
CASC
+$12.6M
2
CTMX icon
CytomX Therapeutics
CTMX
+$10.5M
3
FATE icon
Fate Therapeutics
FATE
+$9.28M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$7.47M
5
TPST icon
Tempest Therapeutics
TPST
+$5.59M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$19.8M
2
ARDX icon
Ardelyx
ARDX
+$18.6M
3
KYNB
Kyntra Bio
KYNB
+$15.7M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15M
5
EDIT icon
Editas Medicine
EDIT
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.89%
2 Miscellaneous 14.11%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$136B
$928K 0.23%
17,060
+8,500
+99% +$466K
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
$859K 0.22%
+118,000
New +$850K
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.74B
$484K 0.12%
35,301
-238,561
-87% -$2.48M
CASC
29
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$430K 0.11%
103,800
– –
OREX
30
DELISTED
Orexigen Therapeutics, Inc.
OREX
$405K 0.1%
+117,726
New +$465K
WVE icon
31
Wave Life Sciences
WVE
$993M
$275K 0.07%
+10,000
New +$279K
FWP
32
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$108K 0.03%
+718
New +$135K
ARDX icon
33
Ardelyx
ARDX
$984M
– –
-1,310,023
Closed -$18.6M
CYTK icon
34
Cytokinetics
CYTK
$10B
– –
-54,879
Closed -$667K
EDIT icon
35
Editas Medicine
EDIT
$485M
– –
-626,762
Closed -$10.2M
FAST icon
36
Fastenal
FAST
$57.1B
– –
-10,148,104
Closed -$6.37M
CMRX
37
DELISTED
Chimerix, Inc.
CMRX
– –
-1,415,687
Closed -$6.51M
TMBR
38
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-89
Closed -$502K
ALXN
39
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-162,200
Closed -$19.8M
FPRX
40
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-298,712
Closed -$15M
AGN
41
CALL
DELISTED
Allergan plc
AGN
– –
-50,000
Closed -$10.5M
DERM
42
DELISTED
Dermira, Inc.
DERM
– –
-43,200
Closed -$1.31M
EGLT
43
DELISTED
Egalet Corporation
EGLT
– –
-222,300
Closed -$1.7M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2017 Portfolio in Review

As of Q1 2017, EcoR1 Capital held 45 positions worth $396M, up 26% from $314M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

EcoR1 Capital withdrew a net $53.8M in Q1 2017, closing 12 positions and reducing 5 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, EcoR1 Capital opened a new position in Cascadian Therapeutics, Inc. worth $12.4M.

  • EcoR1 Capital's largest Q1 2017 buy was Cascadian Therapeutics, Inc.: 3,000,000 shares worth $12.4M.
  • EcoR1 Capital added most to Aclaris Therapeutics in Q1 2017, an estimated $7.47M increase.
  • EcoR1 Capital's biggest Q1 2017 reduction was Kyntra Bio, cutting an estimated $15.7M.
  • EcoR1 Capital fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $19.8M.
  • EcoR1 Capital's ten largest holdings make up 82% of its $396M portfolio in Q1 2017.
  • EcoR1 Capital opened 14 new positions and closed 12 in Q1 2017.
  • EcoR1 Capital's portfolio value rose 26% quarter-over-quarter to $396M.

Based on EcoR1 Capital's 13F filing for Q1 2017, filed 15 May 2017.